Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biogen Pharmachem Industries has filed a regulatory disclosure with BSE confirming that as of September 30, 2025, the company has no unutilized funds remaining from any past public issue, rights issue, preferential issue, or qualified institutional placement (QIP). The company has therefore not provided any deviation/variation statement (Annexure-A), as there is nothing to report. The disclosure is a routine compliance filing under SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015. The filing was signed by Wholetime Director Kelash Bunkar on November 7, 2025.
This is a routine compliance disclosure with no material financial information or impact on shareholders. It simply confirms the company has no pending proceeds from prior fund-raising activities to report on, and is unlikely to affect the stock price.